# Can-Fite BioPharma Ltd.: financial statements, quarterly

CANF · NYSE · CIK 1536196 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/canf.md) · [Financials](/companies/canf/financials.md) · [Filings](/companies/canf/filings.md) · [Insiders](/companies/canf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/canf/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.9](/filings/0001213900-19-005251.md) | [8.1](/filings/0001213900-20-007682.md) | [3.5](/filings/0001213900-21-017630.md) | [3.6](/filings/0001213900-21-017630.md) | [2.7](/filings/0001213900-21-017630.md) | [8.3](/filings/0001213900-22-014672.md) | [4.4](/filings/0001213900-23-024298.md) | [3.0](/filings/0001213900-24-026947.md) | [4.3](/filings/0001213900-25-031298.md) | [4.8](/filings/0001213900-26-034447.md) | [5.5](/filings/0001213900-26-034447.md) |
| Current assets | $m | not reported | not reported | [6.7](/filings/0001213900-19-005251.md) | [7.9](/filings/0001213900-20-007682.md) | [7.1](/filings/0001213900-21-017630.md) | [9.4](/filings/0001213900-22-014672.md) | [20.1](/filings/0001213900-23-024298.md) | [9.2](/filings/0001213900-24-026947.md) | [9.9](/filings/0001213900-25-031298.md) | [9.0](/filings/0001213900-26-034447.md) | [9.4](/filings/0001213900-26-034447.md) |
| Total assets | $m | not reported | not reported | [7.6](/filings/0001213900-19-005251.md) | [8.0](/filings/0001213900-20-007682.md) | [8.2](/filings/0001213900-21-017630.md) | [9.5](/filings/0001213900-22-014672.md) | [20.3](/filings/0001213900-23-024298.md) | [9.3](/filings/0001213900-24-026947.md) | [10.0](/filings/0001213900-25-031298.md) | [9.1](/filings/0001213900-26-034447.md) | [9.5](/filings/0001213900-26-034447.md) |
| Current liabilities | $m | not reported | not reported | [1.8](/filings/0001213900-19-005251.md) | [3.1](/filings/0001213900-20-007682.md) | [3.3](/filings/0001213900-21-017630.md) | [1.3](/filings/0001213900-22-014672.md) | [2.7](/filings/0001213900-23-024298.md) | [2.5](/filings/0001213900-24-026947.md) | [2.0](/filings/0001213900-25-031298.md) | [2.1](/filings/0001213900-26-034447.md) | [2.7](/filings/0001213900-26-034447.md) |
| Shareholders' equity | $m | [13.9](/filings/0001213900-19-005251.md) | [6.0](/filings/0001213900-20-007682.md) | [3.0](/filings/0001213900-21-017630.md) | [3.0](/filings/0001213900-22-014672.md) | [2.4](/filings/0001213900-23-024298.md) | [6.1](/filings/0001213900-24-026947.md) | [14.4](/filings/0001213900-25-031298.md) | [4.5](/filings/0001213900-26-034447.md) | [6.2](/filings/0001213900-26-034447.md) | [5.4](/filings/0001213900-26-034447.md) | [5.6](/filings/0001213900-26-034447.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: ifrs-full:CurrentAssets, us-gaap:AssetsCurrent
- Total assets: ifrs-full:Assets, us-gaap:Assets
- Current liabilities: ifrs-full:CurrentLiabilities, us-gaap:LiabilitiesCurrent
- Shareholders' equity: ifrs-full:Equity, us-gaap:StockholdersEquity

Shares outstanding: 2,618,425 at 2025-12-31, from the cover of the [20-F filed 2026-03-26](/filings/0001213900-26-034447.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.